company background image
KMDA logo

Kamada NasdaqGS:KMDA Stock Report

Last Price

US$6.05

Market Cap

US$346.8m

7D

5.2%

1Y

-0.5%

Updated

24 Dec, 2024

Data

Company Financials +

KMDA Stock Overview

Manufactures and sells plasma-derived protein therapeutics. More details

KMDA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Kamada Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kamada
Historical stock prices
Current Share Price₪6.05
52 Week High₪6.53
52 Week Low₪4.74
Beta0.24
1 Month Change3.07%
3 Month Change14.15%
1 Year Change-0.49%
3 Year Change-10.24%
5 Year Change-11.42%
Change since IPO-34.59%

Recent News & Updates

Recent updates

Kamada secures $22M extension of Canadian supply tender

Oct 19

Kamada Q2 2022 Earnings Preview

Aug 16

Kamada inks agreement for the distribution of three biosimilar products in Israel

Jan 13

Kamada Looks Cheap AS Takeda Deal Creates Value

Nov 02

Shareholder Returns

KMDAUS BiotechsUS Market
7D5.2%-3.3%-0.4%
1Y-0.5%-2.7%24.8%

Return vs Industry: KMDA exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: KMDA underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is KMDA's price volatile compared to industry and market?
KMDA volatility
KMDA Average Weekly Movement3.5%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: KMDA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: KMDA's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990378Amir Londonwww.kamada.com

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.

Kamada Ltd. Fundamentals Summary

How do Kamada's earnings and revenue compare to its market cap?
KMDA fundamental statistics
Market capUS$346.78m
Earnings (TTM)US$15.71m
Revenue (TTM)US$158.38m

22.1x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KMDA income statement (TTM)
RevenueUS$158.38m
Cost of RevenueUS$91.03m
Gross ProfitUS$67.35m
Other ExpensesUS$51.64m
EarningsUS$15.71m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin42.52%
Net Profit Margin9.92%
Debt/Equity Ratio0%

How did KMDA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:39
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kamada Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Anthony PetroneJefferies LLC
David LewisMorgan Stanley